바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

0오늘 방문

738누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

CGTBiologicstaleNationwide Children's HospitalPhase 1

rAAV1.tMCK.human-alpha-sarcoglycan- First cohort (rAAV1.tMCK.human-alpha-sarcoglycan- First cohort)

Muscular Dystrophies · Muscular Dystrophies

#MuscularDystrophies#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

AntibodystaleByondis B.V.Phase 1

pembrolizumab (Keytruda, BYON4228 + Pembrolizumab)

Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Phase1#항체#면역항체+2

임상시험 1상태 RECRUITING

CGTBiologicstaleNationwide Children's HospitalPhase 1

d3990 (rAAV2.5-CMV-minidystrophin, rAAV2.5-CMV-minidystrophin (d3990))

Duchenne Muscular Dystrophy · Duchenne Muscular Dystrophy

#DuchenneMuscularDystrophy#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

CGTAAVBiologicstaleFederal State Budget Institutio…Phase 2

GT-UGT1A1-AAV8-02 (GT-UGT1A1-AAV8-02)

Crigler-Najjar Syndrome Type I · Crigler-Najjar Syndrome Type I

#Crigler-NajjarSyndromeTypeI#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTBiologicstaleM.D. Anderson Cancer CenterPhase 1

TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells (TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells)

Breast Cancer · TROP2

#TROP2#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

ADCBiologicstaleCSPC ZhongQi Pharmaceutical Tec…Phase 1

an antibody drug conjugate (an antibody drug conjugate)

Neoplasms · Neoplasms

#Neoplasms#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

효능 ORR 31.2%임상시험 1상태 ACTIVE

CGTBiologicstaleBeacon TherapeuticsPhase 2

rAAV2tYF-CB-hRS1 (rAAV2tYF-CB-hRS1)

X-linked Retinoschisis · X-linked Retinoschisis

#X-linkedRetinoschisis#CGT#Phase2#세포유전치료#CAR-T+2

효능 ORR 39.5%임상시험 1상태 ACTIVE

CGTBiologicstaleSTZ eyetrialPhase 2

rAAV.hCNGA3 (rAAV.hCNGA3)

Achromatopsia · Achromatopsia

#Achromatopsia#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTAAVBiologicstaleREGENXBIO Inc.Phase 2

AAV directed hLDLR gene therapy (AAV directed hLDLR gene therapy)

Homozygous Familial Hypercholesterolemia (HoFH) · Homozygous Familial Hypercholesterolemia

#HomozygousFamilialHypercholester#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 DISCONTINUED

AntibodystaleFudan UniversityPhase 2

trastuzumab (Herceptin, Paclitaxel polymer micelles combined with trastuzumab, pertuzumab, and adrelumab)

Advanced HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 RECRUITING

CGTAAVBiologicstaleBlackfinBio LtdPhase 2

AAV9-CBh-AP4B1 (BFB-101, BFB-101 (AAV9-CBh-AP4B1))

HSP; Hereditary Spastic Paraplegia · HSP

#HSP#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

AntibodystaleAbbViePhase 3

adalimumab (Humira, Adalimumab every other week)

Plaque Psoriasis · Plaque Psoriasis

#PlaquePsoriasis#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 ACTIVE

ADCBiologicstaleJiangsu Alphamab Biopharmaceuti…Phase 2

Platinum (Platinum)

Cervical Cancer · Cervical Cancer

#CervicalCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

효능 ORR 4.86%임상시험 1상태 RECRUITING

AntibodystaleJanssenPreclinical

ustekinumab (Stelara, Ustekinumab - Standard Dosage)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Preclinical#항체#면역항체+2

임상시험 1상태 ACTIVE

CGTBiologicstaleUniversity of MiamiPhase 2

mTOR inhibitor + Selective estrogen receptor modulator (mTOR inhibitor + Selective estrogen receptor modulator)

Breast Cancer; ER-positive Breast Cancer · HER2

#HER2#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

ADCBiologicstaleNEOK Bio, Inc.Phase 1

NEOK002 (NEOK002)

Locally Advanced (Unresectable) or Metastatic Solid Tumors · Locally Advanced (Unresectable) or Metas

#LocallyAdvancedUnresectableorMet#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

AntibodystaleAbbViePhase 1

adalimumab (Humira, Adalimumab-EU)

Healthy Subjects · Healthy Subjects

#HealthySubjects#Antibody#Phase1#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleTaipei Tzu Chi Hospital, Buddhi…Approved

Omalizimab (Omalizimab)

Asthma Patients · Asthma Patients

#AsthmaPatients#Antibody#Approved#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleAkesoPhase 2

Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine (Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine)

Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 RECRUITING

CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

Anti-Thyroglobulin mTCR PBL (Anti-Thyroglobulin mTCR PBL)

Metastatic Thyroid Cancer · Metastatic Thyroid Cancer

#MetastaticThyroidCancer#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 DISCONTINUED

ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with fruquintinib and Tislelizumab)

HER2-positive Gastric Cancer; Immunotherapy · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 1상태 ACTIVE

ADCBiologicstaleJiangsu Alphamab Biopharmaceuti…Phase 2

JSKN033 (JSKN033)

Cervical Cancer · Cervical Cancer

#CervicalCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes (autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes)

Skin Cancer; Melanoma · Skin Cancer

#SkinCancer#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 DISCONTINUED

CGTBiologicstaleInge Marie SvanePhase 1

ADP-TILIL7 (ADP-TILIL7)

Melanoma Stage III; Melanoma Stage IV · Melanoma Stage III

#MelanomaStageIII#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

AntibodystaleAmgenPhase 2

EGFR inhibitors (panitumumab, panitumumab (EGFR inhibitors))

Recurrence Free Survival · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3

효능 ORR 19%임상시험 1상태 RECRUITING

81 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 0 / 738

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

rAAV1.tMCK.human-alpha-sarcoglycan- First cohort (rAAV1.tMCK.human-alpha-sarcoglycan- First cohort)

pembrolizumab (Keytruda, BYON4228 + Pembrolizumab)

d3990 (rAAV2.5-CMV-minidystrophin, rAAV2.5-CMV-minidystrophin (d3990))

GT-UGT1A1-AAV8-02 (GT-UGT1A1-AAV8-02)

TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells (TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells)

an antibody drug conjugate (an antibody drug conjugate)

rAAV2tYF-CB-hRS1 (rAAV2tYF-CB-hRS1)

rAAV.hCNGA3 (rAAV.hCNGA3)

AAV directed hLDLR gene therapy (AAV directed hLDLR gene therapy)

trastuzumab (Herceptin, Paclitaxel polymer micelles combined with trastuzumab, pertuzumab, and adrelumab)

AAV9-CBh-AP4B1 (BFB-101, BFB-101 (AAV9-CBh-AP4B1))

adalimumab (Humira, Adalimumab every other week)

Platinum (Platinum)

ustekinumab (Stelara, Ustekinumab - Standard Dosage)

mTOR inhibitor + Selective estrogen receptor modulator (mTOR inhibitor + Selective estrogen receptor modulator)

NEOK002 (NEOK002)

adalimumab (Humira, Adalimumab-EU)

Omalizimab (Omalizimab)

Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine (Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine)

Anti-Thyroglobulin mTCR PBL (Anti-Thyroglobulin mTCR PBL)

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with fruquintinib and Tislelizumab)

JSKN033 (JSKN033)

autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes (autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes)

ADP-TILIL7 (ADP-TILIL7)

EGFR inhibitors (panitumumab, panitumumab (EGFR inhibitors))

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

rAAV1.tMCK.human-alpha-sarcoglycan- First cohort (rAAV1.tMCK.human-alpha-sarcoglycan- First cohort)

pembrolizumab (Keytruda, BYON4228 + Pembrolizumab)

d3990 (rAAV2.5-CMV-minidystrophin, rAAV2.5-CMV-minidystrophin (d3990))

GT-UGT1A1-AAV8-02 (GT-UGT1A1-AAV8-02)

TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells (TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells)

an antibody drug conjugate (an antibody drug conjugate)

rAAV2tYF-CB-hRS1 (rAAV2tYF-CB-hRS1)

rAAV.hCNGA3 (rAAV.hCNGA3)

AAV directed hLDLR gene therapy (AAV directed hLDLR gene therapy)

trastuzumab (Herceptin, Paclitaxel polymer micelles combined with trastuzumab, pertuzumab, and adrelumab)

AAV9-CBh-AP4B1 (BFB-101, BFB-101 (AAV9-CBh-AP4B1))

adalimumab (Humira, Adalimumab every other week)

Platinum (Platinum)

ustekinumab (Stelara, Ustekinumab - Standard Dosage)

mTOR inhibitor + Selective estrogen receptor modulator (mTOR inhibitor + Selective estrogen receptor modulator)

NEOK002 (NEOK002)

adalimumab (Humira, Adalimumab-EU)

Omalizimab (Omalizimab)

Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine (Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine)

Anti-Thyroglobulin mTCR PBL (Anti-Thyroglobulin mTCR PBL)

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with fruquintinib and Tislelizumab)

JSKN033 (JSKN033)

autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes (autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes)

ADP-TILIL7 (ADP-TILIL7)

EGFR inhibitors (panitumumab, panitumumab (EGFR inhibitors))

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

rAAV1.tMCK.human-alpha-sarcoglycan- First cohort (rAAV1.tMCK.human-alpha-sarcoglycan- First cohort)

pembrolizumab (Keytruda, BYON4228 + Pembrolizumab)

d3990 (rAAV2.5-CMV-minidystrophin, rAAV2.5-CMV-minidystrophin (d3990))

GT-UGT1A1-AAV8-02 (GT-UGT1A1-AAV8-02)

TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells (TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells)

an antibody drug conjugate (an antibody drug conjugate)

rAAV2tYF-CB-hRS1 (rAAV2tYF-CB-hRS1)

rAAV.hCNGA3 (rAAV.hCNGA3)

AAV directed hLDLR gene therapy (AAV directed hLDLR gene therapy)

trastuzumab (Herceptin, Paclitaxel polymer micelles combined with trastuzumab, pertuzumab, and adrelumab)

AAV9-CBh-AP4B1 (BFB-101, BFB-101 (AAV9-CBh-AP4B1))

adalimumab (Humira, Adalimumab every other week)

Platinum (Platinum)

ustekinumab (Stelara, Ustekinumab - Standard Dosage)

mTOR inhibitor + Selective estrogen receptor modulator (mTOR inhibitor + Selective estrogen receptor modulator)

NEOK002 (NEOK002)